Search

Your search keyword '"Azzabi, Ashraf"' showing total 32 results
Start Over Author "Azzabi, Ashraf"
32 results on '"Azzabi, Ashraf"'

1. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Author

Jones, Elin, Hyde, Katherine, Glen, Hilary, Needleman, Sarah, McGovern, Ursula, Sheehan, Denise, Paisey, Sangeeta, Shaffer, Richard, Beresford, Mark, Malik, Zafar, Zarkar, Anjali, Porfiri, Emilio, Fackrell, David, Lee, Ling, Sreenivasan, Thiagarajan, Brock, Sue, Brown, Simon, Bahl, Amit, Smith-Howell, Mike, Woodward, Cathryn, Phan, Mau-Don, Mazhar, Danish, Narahari, Krishna, Tanguay, Jacob, Douglas, Fiona, Kumar, Anil, Hamid, Abdel, Ibrahim, Azman, Muthukumar, Dakshinamoorthy, Simms, Matthew, Worlding, Jane, Tran, Anna, Kagzi, Mohammed, Das, Prantik, Pezaro, Carmel, Sivoglo, Virgil, Masters, Benjamin, Keng-Koh, Pek, Manetta, Caroline, McLaren, Duncan, Gupta, Nishi, Boussios, Stergios, Taylor, Henry, Graham, John, Perna, Carla, Melcher, Lucinda, Grant, Warren, Sabharwal, Ami, Hofmann, Uschi, Dealey, Robert, McPhail, Neil, Brierly, Robert, Capaldi, Lisa, Sidek, Norma, Whelan, Peter, Robson, Peter, Falconer, Alison, Rudman, Sarah, Vivekanandan, Sindu, Mullessey, Vinod, Vilarino-Varela, Maria, Khoo, Vincent, Tipples, Karen, Afshar, Mehran, Brulinski, Patryk, Sangar, Vijay, Peedell, Clive, Azzabi, Ashraf, Hoskin, Peter, Mullassery, Viwod, Sundar, Santhanam, Khan, Yakhub, Conroy, Ruth, Protheroe, Andrew, Carser, Judith, Rogers, Paul, Tarver, Kathryn, Gibbs, Stephanie, Khan, Mohammad Muneeb, Hingorani, Mohan, Crabb, Simon, Alameddine, Manal, Bhalla, Neeraj, Hughes, Robert, Logue, John, Leaning, Darren, Vengalil, Salil, Ford, Daniel, Walker, Georgina, Shaheen, Ahmed, Khan, Omar, Chan, Andrew, Ahmed, Imtiaz, Hilman, Serena, Sayers, Ian, Nikapota, Ashok, Bloomfield, David, Porter, Tim, Joseph, Joji, Rentsch, Cyrill, Pereira Mestre, Ricardo, Roggero, Enrico, Beyer, Jörg, Borner, Markus, Strebel, Raeto, Berthold, Dominik, Engeler, Daniel, John, Hubert, Popescu, Razvan, Durr, Donat, Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Sachdeva, Ashwin, Jones, Craig, Hoyle, Alex, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Gilson, Clare, Rush, Hannah, Abdel-Aty, Hoda, Amos, Claire L, Murphy, Claire, Chowdhury, Simon, Russell, J Martin, Parkar, Nazia, Pugh, Cheryl, Diaz-Montana, Carlos, Saxby, Helen, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Wagstaff, John, Gray, Emma, Alzouebi, Mymoona, Parikh, Omi, Robinson, Angus, Montazeri, Amir H, Wylie, James, Cathomas, Richard, Brown, Michael D, Jain, Yatin, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, and James, Nicholas D

Published
2023
Full Text
View/download PDF

2. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Author

Jones, Elin, Hyde, Katherine, Glen, Hilary, Needleman, Sarah, McGovern, Ursula, Sheehan, Denise, Paisey, Sangeeta, Shaffer, Richard, Beresford, Mark, Malik, Zafar, Zarkar, Anjali, Porfiri, Emilio, Fackrell, David, Lee, Ling, Sreenivasan, Thiagarajan, Brock, Sue, Brown, Simon, Bahl, Amit, Smith-Howell, Mike, Woodward, Cathryn, Phan, Mau-Don, Mazhar, Danish, Narahari, Krishna, Tanguay, Jacob, Douglas, Fiona, Kumar, Anil, Hamid, Abdel, Ibrahim, Azman, Muthukumar, Dakshinamoorthy, Simms, Matthew, Worlding, Jane, Tran, Anna, Kagzi, Mohammed, Das, Prantik, Pezaro, Carmel, Sivoglo, Virgil, Masters, Benjamin, Keng-Koh, Pek, Manetta, Caroline, McLaren, Duncan, Gupta, Nishi, Boussios, Stergios, Taylor, Henry, Graham, John, Perna, Carla, Melcher, Lucinda, Grant, Warren, Sabharwal, Ami, Hofmann, Uschi, Dealey, Robert, McPhail, Neil, Brierly, Robert, Capaldi, Lisa, Sidek, Norma, Whelan, Peter, Robson, Peter, Falconer, Alison, Rudman, Sarah, Vivekanandan, Sindu, Mullessey, Vinod, Vilarino-Varela, Maria, Khoo, Vincent, Tipples, Karen, Afshar, Mehran, Brulinski, Patryk, Sangar, Vijay, Peedell, Clive, Azzabi, Ashraf, Hoskin, Peter, Mullassery, Viwod, Sundar, Santhanam, Khan, Yakhub, Conroy, Ruth, Protheroe, Andrew, Carser, Judith, Rogers, Paul, Tarver, Kathryn, Gibbs, Stephanie, Khan, Mohammad Muneeb, Hingorani, Mohan, Crabb, Simon, Alameddine, Manal, Bhalla, Neeraj, Hughes, Robert, Logue, John, Leaning, Darren, Vengalil, Salil, Ford, Daniel, Walker, Georgina, Shaheen, Ahmed, Khan, Omar, Chan, Andrew, Ahmed, Imtiaz, Hilman, Serena, Sayers, Ian, Nikapota, Ashok, Bloomfield, David, Porter, Tim, Joseph, Joji, Rentsch, Cyrill, Pereira Mestre, Ricardo, Roggero, Enrico, Beyer, Jörg, Borner, Markus, Strebel, Raeto, Berthold, Dominik, Engeler, Daniel, John, Hubert, Popescu, Razvan, Durr, Donat, Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L, Atako, Nafisah, Pugh, Cheryl, Buckner, Michelle, Chowdhury, Simon, Russell, J Martin, Gilson, Clare, Rush, Hannah, Bowen, Jo, Lydon, Anna, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Wagstaff, John, Gray, Emma, Alzoueb, Mymoona, Parikh, Omi, Robinson, Angus, Syndikus, Isabel, Wylie, James, Thalmann, George, de Bono, Johann S, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, and James, Nicholas D

Published
2022
Full Text
View/download PDF

3. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

Author

Adams, Lisa, Adlard, Julian, Alfonso, Rosa, Ali, Saira, Andrew, Angela, Araújo, Luís, Azam, Nazya, Ball, Darran, Barker, Queenstone, Basevitch, Alon, Benton, Barbara, Berlin, Cheryl, Bermingham, Nicola, Biller, Leah, Bloss, Angela, Bradford, Matilda, Bradshaw, Nicola, Branson, Amy, Brendler, Charles, Brennan, Maria, Bulman, Barbara, Burgess, Lucy, Cahill, Declan, Callard, Alice, Calvo Verges, Nuria, Cardoso, Marta, Carter, Vanda, Catanzaro, Mario, Chamberlain, Anthony, Chapman, Cyril, Chong, Michael, Clark, Caroline, Clowes, Virginia, Cogley, Lyn, Cole, Trevor, Compton, Cecilia, Conner, Tom, Cookson, Sandra, Cornford, Philip, Costello, Philandra, Coulier, Laura, Davies, Michaela, Dechet, Christopher, DeSouza, Bianca, Devlin, Gemma, Douglas, Fiona, Douglas, Emma, Dudakia, Darshna, Duncan, Alexis, Ellery, Natalie, Everest, Sarah, Freemantle, Sue, Frydenberg, Mark, Fuller, Debbie, Gabriel, Camila, Gale, Madeline, Garcia, Lynda, Gay, Simona, Genova, Elena, George, Angela, Georgiou, Demetra, Gisbert, Alexandra, Gleeson, Margaret, Glover, Wayne, Gnanapragasam, Vincent, Goff, Sally, Goldgar, David, Gonçalves, Nuno, Goodman, Selina, Gorrie, Jennifer, Gott, Hannah, Grant, Anna, Gray, Catherine, Griffiths, Julie, Gupwell, Karin, Gurasashvili, Jana, Hanslien, Eldbjørg, Haraldsdottir, Sigurdis, Hart, Rachel, Hartigan, Catherine, Hawkes, Lara, Heaton, Tricia, Henderson, Alex, Henrique, Rui, Hilario, Kathrine, Hill, Kathryn, Hulick, Peter, Hunt, Clare, Hutchings, Melanie, Ibitoye, Rita, Inglehearn, Thomas, Ireland, Joanna, Islam, Farah, Ismail, Siti, Jacobs, Chris, James, Denzil, Jenkins, Sharon, Jobson, Irene, Johnstone, Anne, Jones, Oliver, Josefsberg Ben-Yehoshua, Sagi, Kaemba, Beckie, Kaul, Karen, Kemp, Zoe, Kinsella, Netty, Klehm, Margaret, Kockelbergh, Roger, Kohut, Kelly, Kosicka-Slawinska, Monika, Kulkarni, Anjana, Kumar, Pardeep, Lam, Jimmy, LeButt, Mandy, Leibovici, Dan, Lim, Ramona, Limb, Lauren, Lomas, Claire, Longmuir, Mark, López, Consol, Magnani, Tiziana, Maia, Sofia, Maiden, Jessica, Male, Alison, Manalo, Merrie, Martin, Phoebe, McBride, Donna, McGuire, Michael, McMahon, Romayne, McNally, Claire, McVeigh, Terri, Melzer, Ehud, Mencias, Mark, Mercer, Catherine, Mitchell, Gillian, Mora, Josefina, Morton, Catherine, Moss, Cathryn, Murphy, Morgan, Murphy, Declan, Mzazi, Shumi, Nadolski, Maria, Newlin, Anna, Nogueira, Pedro, O'Keefe, Rachael, O'Toole, Karen, O'Connell, Shona, Ogden, Chris, Okoth, Linda, Oliveira, Jorge, Paez, Edgar, Palou, Joan, Park, Linda, Patel, Nafisa, Paulo Souto, João, Pearce, Allison, Peixoto, Ana, Perez, Kimberley, Petelin, Lara, Pichert, Gabriella, Poile, Charlotte, Potter, Alison, Preitner, Nadia, Purnell, Helen, Quinn, Ellen, Radice, Paolo, Rankin, Brigette, Rees, Katie, Renton, Caroline, Richardson, Kate, Risby, Peter, Rogers, Jason, Ruderman, Maggie, Ruiz, April, Sajoo, Anaar, Salvatore, Natale, Sands, Victoria, Sanguedolce, Francesco, Sattar, Ayisha, Saunders, Kathryn, Schofield, Lyn, Scott, Rodney, Searle, Anne, Sehra, Ravinder, Selkirk, Christina, Shackleton, Kylie, Shanley, Sue, Shaw, Adam, Shevrin, Daniel, Shipman, Hannah, Sidat, Zahirah, Siguake, Kas, Simon, Kate, Smyth, Courtney, Snadden, Lesley, Solanky, Nita, Solomons, Joyce, Sorrentino, Margherita, Stayner, Barbara, Stephenson, Robert, Stoffel, Elena, Thomas, Maggie, Thompson, Alan, Tidey, Lizzie, Tischkowitz, Marc, Torokwa, Audrey, Townshend, Sharron, Treherne, Katy, Tricker, Karen, Trinh, Quoc-Dien, Tripathi, Vishakha, Turnbull, Clare, Valdagni, Riccardo, Van As, Nicholas, Venne, Vickie, Verdon, Lizzie, Vitellaro, Marco, Vogel, Kristen, Walker, Lisa, Watford, Amy, Watt, Cathy, Weintroub, Ilana, Weiss, Shelly, Weissman, Scott, Weston, Michelle, Wiggins, Jennifer, Wise, Gillian, Woodhouse, Christopher, Yesildag, Pembe, Youngs, Alice, Yurgelun, Matthew, Zollo, Fabiana, Bancroft, Elizabeth K, Page, Elizabeth C, Brook, Mark N, Thomas, Sarah, Taylor, Natalie, Pope, Jennifer, McHugh, Jana, Jones, Ann-Britt, Karlsson, Questa, Merson, Susan, Ong, Kai Ren, Hoffman, Jonathan, Huber, Camilla, Maehle, Lovise, Grindedal, Eli Marie, Stormorken, Astrid, Evans, D Gareth, Rothwell, Jeanette, Lalloo, Fiona, Brady, Angela F, Bartlett, Marion, Snape, Katie, Hanson, Helen, James, Paul, McKinley, Joanne, Mascarenhas, Lyon, Syngal, Sapna, Ukaegbu, Chinedu, Side, Lucy, Thomas, Tessy, Barwell, Julian, Teixeira, Manuel R, Izatt, Louise, Suri, Mohnish, Macrae, Finlay A, Poplawski, Nicola, Chen-Shtoyerman, Rakefet, Ahmed, Munaza, Musgrave, Hannah, Nicolai, Nicola, Greenhalgh, Lynn, Brewer, Carole, Pachter, Nicholas, Spigelman, Allan D, Azzabi, Ashraf, Helfand, Brian T, Halliday, Dorothy, Buys, Saundra, Ramon y Cajal, Teresa, Donaldson, Alan, Cooney, Kathleen A, Harris, Marion, McGrath, John, Davidson, Rosemarie, Taylor, Amy, Cooke, Peter, Myhill, Kathryn, Hogben, Matthew, Aaronson, Neil K, Ardern-Jones, Audrey, Bangma, Chris H, Castro, Elena, Dearnaley, David, Dias, Alexander, Dudderidge, Tim, Eccles, Diana M, Green, Kate, Eyfjord, Jorunn, Falconer, Alison, Foster, Christopher S, Gronberg, Henrik, Hamdy, Freddie C, Johannsson, Oskar, Khoo, Vincent, Lilja, Hans, Lindeman, Geoffrey J, Lubinski, Jan, Axcrona, Karol, Mikropoulos, Christos, Mitra, Anita V, Moynihan, Clare, Ni Raghallaigh, Holly, Rennert, Gad, Collier, Rebecca, Offman, Judith, Kote-Jarai, Zsofia, and Eeles, Rosalind A

Published
2021
Full Text
View/download PDF

4. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Author

Genetica Klinische Genetica, Cancer, Genetica Sectie Genoomdiagnostiek, Bancroft, Elizabeth K., Page, Elizabeth C., Brook, Mark N., Pope, Jennifer, Thomas, Sarah, Myhill, Kathryn, Helfand, Brian T., Talaty, Pooja, Ong, Kai Ren, Douglas, Emma, Cook, Jackie, Rosario, Derek J., Salinas, Monica, Buys, Saundra S., Anson, Jo, Davidson, Rosemarie, Longmuir, Mark, Side, Lucy, Eccles, Diana M., Tischkowitz, Marc, Taylor, Amy, Cruellas, Mara, Ballestero, Eduard Perez, Cleaver, Ruth, Varughese, Mohini, Barwell, Julian, LeButt, Mandy, Greenhalgh, Lynn, Hart, Rachel, Azzabi, Ashraf, Jobson, Irene, Cogley, Lynn, Evans, D. Gareth, Rothwell, Jeanette, Taylor, Natalie, Hogben, Matthew, Saya, Sibel, Ausems, Margreet G.E.M., Van der Luijt, Rob B., Lock, M. T.W.T., IMPACT Study Steering Committee; IMPACT Collaborators, Genetica Klinische Genetica, Cancer, Genetica Sectie Genoomdiagnostiek, Bancroft, Elizabeth K., Page, Elizabeth C., Brook, Mark N., Pope, Jennifer, Thomas, Sarah, Myhill, Kathryn, Helfand, Brian T., Talaty, Pooja, Ong, Kai Ren, Douglas, Emma, Cook, Jackie, Rosario, Derek J., Salinas, Monica, Buys, Saundra S., Anson, Jo, Davidson, Rosemarie, Longmuir, Mark, Side, Lucy, Eccles, Diana M., Tischkowitz, Marc, Taylor, Amy, Cruellas, Mara, Ballestero, Eduard Perez, Cleaver, Ruth, Varughese, Mohini, Barwell, Julian, LeButt, Mandy, Greenhalgh, Lynn, Hart, Rachel, Azzabi, Ashraf, Jobson, Irene, Cogley, Lynn, Evans, D. Gareth, Rothwell, Jeanette, Taylor, Natalie, Hogben, Matthew, Saya, Sibel, Ausems, Margreet G.E.M., Van der Luijt, Rob B., Lock, M. T.W.T., and IMPACT Study Steering Committee; IMPACT Collaborators

Published
2024

5. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial

Author

Gögenur, Mikail, Rosen, Andreas Weinberger, Iveson, Timothy, Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, Pearson, Sarah, Boyd, Kathleen A., Briggs, Andrew H., Waterston, Ashita, Medley, Louise, Ellis, Richard, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Cunningham, David, Hickish, Tamas, Gollins, Simon, Wasan, Harpreet S., Kelly, Caroline, Gögenur, Ismail, and Holländer, Niels Henrik

Abstract

IMPORTANCE: The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, with no consensus on the optimal time from surgery to adjuvant chemotherapy. OBJECTIVE: To analyze the association between the timing of adjuvant chemotherapy after surgery for colorectal cancer and disease-free survival. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of the phase 3 SCOT randomized clinical trial, from 244 centers in 6 countries, investigating the noninferiority of 3 vs 6 months of adjuvant chemotherapy. Patients with high-risk stage II or stage III nonmetastatic colorectal cancer who underwent curative-intended surgery were randomized to either 3 or 6 months of adjuvant chemotherapy consisting of fluoropyrimidine and oxaliplatin regimens. Those with complete information on the date of surgery, treatment type, and long-term follow-up were investigated for the primary and secondary end points. Data were analyzed from May 2022 to February 2024. INTERVENTION: In the post hoc analysis, patients were grouped according to the start of adjuvant chemotherapy being less than 6 weeks vs greater than 6 weeks after surgery. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival. The secondary end points were adverse events in the total treatment period or the first cycle of adjuvant chemotherapy. RESULTS: A total of 5719 patients (2251 [39.4%] female; mean [SD] age, 63.4 [9.3] years) were included in the primary analysis after data curation; among them, 914 were in the early-start group and 4805 were in the late-start group. Median (IQR) follow-up was 72.0 (47.3-88.1) months, with a median (IQR) of 56 (41-66) days from surgery to chemotherapy. Five-year disease-free survival was 78.0% (95% CI, 75.3%-80.8%) in the early-start group and 73.2% (95% CI, 72.0%-74.5%) in the late-start group. In an adjusted Cox regression analysis, the start of adjuvant chemotherapy greater than 6 weeks after surgery was associated with worse disease-free survival (hazard ratio, 1.24; 95% CI, 1.06-1.46; P = .01). In adjusted logistic regression models, there was no association with adverse events in the total treatment period (odds ratio, 0.82; 95% CI, 0.65-1.04; P = .09) or adverse events in the first cycle of treatment (odds ratio, 0.77; 95% CI, 0.56-1.09; P = .13). CONCLUSIONS AND RELEVANCE: In this international population of patients with high-risk stage II and stage III colorectal cancer, starting adjuvant chemotherapy more than 6 weeks after surgery was associated with worse disease-free survival, with no difference in adverse events between the groups. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN59757862

Published
2024
Full Text
View/download PDF

7. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Author

Robles-Zurita, José, Boyd, Kathleen A., Briggs, Andrew H., Iveson, Timothy, Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Segelov, Eva, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Pearson, Sarah, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Hughes, Rob, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, and Paul, James

Published
2018
Full Text
View/download PDF

8. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Author

Attard, Gerhardt, primary, Murphy, Laura, additional, Clarke, Noel W, additional, Sachdeva, Ashwin, additional, Jones, Craig, additional, Hoyle, Alex, additional, Cross, William, additional, Jones, Robert J, additional, Parker, Christopher C, additional, Gillessen, Silke, additional, Cook, Adrian, additional, Brawley, Chris, additional, Gilson, Clare, additional, Rush, Hannah, additional, Abdel-Aty, Hoda, additional, Amos, Claire L, additional, Murphy, Claire, additional, Chowdhury, Simon, additional, Malik, Zafar, additional, Russell, J Martin, additional, Parkar, Nazia, additional, Pugh, Cheryl, additional, Diaz-Montana, Carlos, additional, Pezaro, Carmel, additional, Grant, Warren, additional, Saxby, Helen, additional, Pedley, Ian, additional, O'Sullivan, Joe M, additional, Birtle, Alison, additional, Gale, Joanna, additional, Srihari, Narayanan, additional, Thomas, Carys, additional, Tanguay, Jacob, additional, Wagstaff, John, additional, Das, Prantik, additional, Gray, Emma, additional, Alzouebi, Mymoona, additional, Parikh, Omi, additional, Robinson, Angus, additional, Montazeri, Amir H, additional, Wylie, James, additional, Zarkar, Anjali, additional, Cathomas, Richard, additional, Brown, Michael D, additional, Jain, Yatin, additional, Dearnaley, David P, additional, Mason, Malcolm D, additional, Gilbert, Duncan, additional, Langley, Ruth E, additional, Millman, Robin, additional, Matheson, David, additional, Sydes, Matthew R, additional, Brown, Louise C, additional, Parmar, Mahesh K B, additional, James, Nicholas D, additional, Jones, Elin, additional, Hyde, Katherine, additional, Glen, Hilary, additional, Needleman, Sarah, additional, McGovern, Ursula, additional, Sheehan, Denise, additional, Paisey, Sangeeta, additional, Shaffer, Richard, additional, Beresford, Mark, additional, Porfiri, Emilio, additional, Fackrell, David, additional, Lee, Ling, additional, Sreenivasan, Thiagarajan, additional, Brock, Sue, additional, Brown, Simon, additional, Bahl, Amit, additional, Smith-Howell, Mike, additional, Woodward, Cathryn, additional, Phan, Mau-Don, additional, Mazhar, Danish, additional, Narahari, Krishna, additional, Douglas, Fiona, additional, Kumar, Anil, additional, Hamid, Abdel, additional, Ibrahim, Azman, additional, Muthukumar, Dakshinamoorthy, additional, Simms, Matthew, additional, Worlding, Jane, additional, Tran, Anna, additional, Kagzi, Mohammed, additional, Sivoglo, Virgil, additional, Masters, Benjamin, additional, Keng-Koh, Pek, additional, Manetta, Caroline, additional, McLaren, Duncan, additional, Gupta, Nishi, additional, Boussios, Stergios, additional, Taylor, Henry, additional, Graham, John, additional, Perna, Carla, additional, Melcher, Lucinda, additional, Sabharwal, Ami, additional, Hofmann, Uschi, additional, Dealey, Robert, additional, McPhail, Neil, additional, Brierly, Robert, additional, Capaldi, Lisa, additional, Sidek, Norma, additional, Whelan, Peter, additional, Robson, Peter, additional, Falconer, Alison, additional, Rudman, Sarah, additional, Vivekanandan, Sindu, additional, Mullessey, Vinod, additional, Vilarino-Varela, Maria, additional, Khoo, Vincent, additional, Tipples, Karen, additional, Afshar, Mehran, additional, Brulinski, Patryk, additional, Sangar, Vijay, additional, Peedell, Clive, additional, Azzabi, Ashraf, additional, Hoskin, Peter, additional, Mullassery, Viwod, additional, Sundar, Santhanam, additional, Khan, Yakhub, additional, Conroy, Ruth, additional, Protheroe, Andrew, additional, Carser, Judith, additional, Rogers, Paul, additional, Tarver, Kathryn, additional, Gibbs, Stephanie, additional, Khan, Mohammad Muneeb, additional, Hingorani, Mohan, additional, Crabb, Simon, additional, Alameddine, Manal, additional, Bhalla, Neeraj, additional, Hughes, Robert, additional, Logue, John, additional, Leaning, Darren, additional, Vengalil, Salil, additional, Ford, Daniel, additional, Walker, Georgina, additional, Shaheen, Ahmed, additional, Khan, Omar, additional, Chan, Andrew, additional, Ahmed, Imtiaz, additional, Hilman, Serena, additional, Sayers, Ian, additional, Nikapota, Ashok, additional, Bloomfield, David, additional, Porter, Tim, additional, Joseph, Joji, additional, Rentsch, Cyrill, additional, Pereira Mestre, Ricardo, additional, Roggero, Enrico, additional, Beyer, Jörg, additional, Borner, Markus, additional, Strebel, Raeto, additional, Berthold, Dominik, additional, Engeler, Daniel, additional, John, Hubert, additional, Popescu, Razvan, additional, and Durr, Donat, additional

Published
2023
Full Text
View/download PDF

9. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Author

Brown, Janet E, primary, Royle, Kara-Louise, additional, Gregory, Walter, additional, Ralph, Christy, additional, Maraveyas, Anthony, additional, Din, Omar, additional, Eisen, Timothy, additional, Nathan, Paul, additional, Powles, Tom, additional, Griffiths, Richard, additional, Jones, Robert, additional, Vasudev, Naveen, additional, Wheater, Matthew, additional, Hamid, Abdel, additional, Waddell, Tom, additional, McMenemin, Rhona, additional, Patel, Poulam, additional, Larkin, James, additional, Faust, Guy, additional, Martin, Adam, additional, Swain, Jayne, additional, Bestall, Janine, additional, McCabe, Christopher, additional, Meads, David, additional, Goh, Vicky, additional, Min Wah, Tze, additional, Brown, Julia, additional, Hewison, Jenny, additional, Selby, Peter, additional, Collinson, Fiona, additional, Carser, Judith, additional, Srinivasan, Gopalakrishnan, additional, Thistlewaite, Fiona, additional, Azzabi, Ashraf, additional, Beresford, Mark, additional, Farrugia, David, additional, Decatris, Marios, additional, Thomas, Carys, additional, Gale, Joanna, additional, McAleer, James, additional, Clayton, Alison, additional, Boleti, Ekaterini, additional, Geldart, Thomas, additional, Sundar, Santhanam, additional, Lester, Jason, additional, Palaniappan, Nachi, additional, Hingorani, Mohan, additional, Rehman, Khaliq, additional, Khan, Mohammad, additional, Sarwar, Naveed, additional, Graham, Janine, additional, Thomson, Alastair, additional, Srihari, Narayanan, additional, Sheehan, Denise, additional, Srinivasan, Rajaguru, additional, Khan, Omar, additional, Jane Worlding, Andrew Stockdale, additional, Boussios, Stergios, additional, Stuart, Nicholas, additional, MacDonald-Smith, Carey, additional, Danwata, Falalu, additional, McLaren, Duncan, additional, Sundaramurthy, Aravindhan, additional, Lydon, Anna, additional, Beesley, Sharon, additional, Lees, Kathryn, additional, Varughese, Mohini, additional, Gray, Emma, additional, Scott, Angela, additional, Baxter, Mark, additional, Mullard, Anna, additional, Innominato, Pasquale, additional, Kapur, Gaurav, additional, Kumar, Anil, additional, Charnley, Natalie, additional, Manetta, Caroline, additional, Chakraborti, Prabir, additional, Das, Prantik, additional, Rudman, Sarah, additional, Taylor, Henry, additional, Mikropoulos, Christos, additional, Highley, Martin, additional, Muthukumar, Dakshinamoorthy, additional, Zarkar, Anjali, additional, Vergis, Roy, additional, Sriprasad, Seshadri, additional, Brulinski, Patryk, additional, Clarke, Amanda, additional, Osbourne, Richard, additional, Harvey, Melanie, additional, Dega, Renata, additional, Sparrow, Geoffrey, additional, Barthakur, Urmila, additional, Beaumont, Erica, additional, Michael, Agnieszka, additional, Porfiri, Emilio, additional, Azam, Faisal, additional, and Kodavtiganti, Ravi, additional

Published
2023
Full Text
View/download PDF

11. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Author

Attard, Gerhardt, primary, Murphy, Laura, additional, Clarke, Noel W, additional, Cross, William, additional, Jones, Robert J, additional, Parker, Christopher C, additional, Gillessen, Silke, additional, Cook, Adrian, additional, Brawley, Chris, additional, Amos, Claire L, additional, Atako, Nafisah, additional, Pugh, Cheryl, additional, Buckner, Michelle, additional, Chowdhury, Simon, additional, Malik, Zafar, additional, Russell, J Martin, additional, Gilson, Clare, additional, Rush, Hannah, additional, Bowen, Jo, additional, Lydon, Anna, additional, Pedley, Ian, additional, O'Sullivan, Joe M, additional, Birtle, Alison, additional, Gale, Joanna, additional, Srihari, Narayanan, additional, Thomas, Carys, additional, Tanguay, Jacob, additional, Wagstaff, John, additional, Das, Prantik, additional, Gray, Emma, additional, Alzoueb, Mymoona, additional, Parikh, Omi, additional, Robinson, Angus, additional, Syndikus, Isabel, additional, Wylie, James, additional, Zarkar, Anjali, additional, Thalmann, George, additional, de Bono, Johann S, additional, Dearnaley, David P, additional, Mason, Malcolm D, additional, Gilbert, Duncan, additional, Langley, Ruth E, additional, Millman, Robin, additional, Matheson, David, additional, Sydes, Matthew R, additional, Brown, Louise C, additional, Parmar, Mahesh K B, additional, James, Nicholas D, additional, Jones, Elin, additional, Hyde, Katherine, additional, Glen, Hilary, additional, Needleman, Sarah, additional, McGovern, Ursula, additional, Sheehan, Denise, additional, Paisey, Sangeeta, additional, Shaffer, Richard, additional, Beresford, Mark, additional, Porfiri, Emilio, additional, Fackrell, David, additional, Lee, Ling, additional, Sreenivasan, Thiagarajan, additional, Brock, Sue, additional, Brown, Simon, additional, Bahl, Amit, additional, Smith-Howell, Mike, additional, Woodward, Cathryn, additional, Phan, Mau-Don, additional, Mazhar, Danish, additional, Narahari, Krishna, additional, Douglas, Fiona, additional, Kumar, Anil, additional, Hamid, Abdel, additional, Ibrahim, Azman, additional, Muthukumar, Dakshinamoorthy, additional, Simms, Matthew, additional, Worlding, Jane, additional, Tran, Anna, additional, Kagzi, Mohammed, additional, Pezaro, Carmel, additional, Sivoglo, Virgil, additional, Masters, Benjamin, additional, Keng-Koh, Pek, additional, Manetta, Caroline, additional, McLaren, Duncan, additional, Gupta, Nishi, additional, Boussios, Stergios, additional, Taylor, Henry, additional, Graham, John, additional, Perna, Carla, additional, Melcher, Lucinda, additional, Grant, Warren, additional, Sabharwal, Ami, additional, Hofmann, Uschi, additional, Dealey, Robert, additional, McPhail, Neil, additional, Brierly, Robert, additional, Capaldi, Lisa, additional, Sidek, Norma, additional, Whelan, Peter, additional, Robson, Peter, additional, Falconer, Alison, additional, Rudman, Sarah, additional, Vivekanandan, Sindu, additional, Mullessey, Vinod, additional, Vilarino-Varela, Maria, additional, Khoo, Vincent, additional, Tipples, Karen, additional, Afshar, Mehran, additional, Brulinski, Patryk, additional, Sangar, Vijay, additional, Peedell, Clive, additional, Azzabi, Ashraf, additional, Hoskin, Peter, additional, Mullassery, Viwod, additional, Sundar, Santhanam, additional, Khan, Yakhub, additional, Conroy, Ruth, additional, Protheroe, Andrew, additional, Carser, Judith, additional, Rogers, Paul, additional, Tarver, Kathryn, additional, Gibbs, Stephanie, additional, Khan, Mohammad Muneeb, additional, Hingorani, Mohan, additional, Crabb, Simon, additional, Alameddine, Manal, additional, Bhalla, Neeraj, additional, Hughes, Robert, additional, Logue, John, additional, Leaning, Darren, additional, Vengalil, Salil, additional, Ford, Daniel, additional, Walker, Georgina, additional, Shaheen, Ahmed, additional, Khan, Omar, additional, Chan, Andrew, additional, Ahmed, Imtiaz, additional, Hilman, Serena, additional, Sayers, Ian, additional, Nikapota, Ashok, additional, Bloomfield, David, additional, Porter, Tim, additional, Joseph, Joji, additional, Rentsch, Cyrill, additional, Pereira Mestre, Ricardo, additional, Roggero, Enrico, additional, Beyer, Jörg, additional, Borner, Markus, additional, Strebel, Raeto, additional, Berthold, Dominik, additional, Engeler, Daniel, additional, John, Hubert, additional, Popescu, Razvan, additional, and Durr, Donat, additional

Published
2022
Full Text
View/download PDF

12. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

Author

Bancroft, Elizabeth K, primary, Page, Elizabeth C, additional, Brook, Mark N, additional, Thomas, Sarah, additional, Taylor, Natalie, additional, Pope, Jennifer, additional, McHugh, Jana, additional, Jones, Ann-Britt, additional, Karlsson, Questa, additional, Merson, Susan, additional, Ong, Kai Ren, additional, Hoffman, Jonathan, additional, Huber, Camilla, additional, Maehle, Lovise, additional, Grindedal, Eli Marie, additional, Stormorken, Astrid, additional, Evans, D Gareth, additional, Rothwell, Jeanette, additional, Lalloo, Fiona, additional, Brady, Angela F, additional, Bartlett, Marion, additional, Snape, Katie, additional, Hanson, Helen, additional, James, Paul, additional, McKinley, Joanne, additional, Mascarenhas, Lyon, additional, Syngal, Sapna, additional, Ukaegbu, Chinedu, additional, Side, Lucy, additional, Thomas, Tessy, additional, Barwell, Julian, additional, Teixeira, Manuel R, additional, Izatt, Louise, additional, Suri, Mohnish, additional, Macrae, Finlay A, additional, Poplawski, Nicola, additional, Chen-Shtoyerman, Rakefet, additional, Ahmed, Munaza, additional, Musgrave, Hannah, additional, Nicolai, Nicola, additional, Greenhalgh, Lynn, additional, Brewer, Carole, additional, Pachter, Nicholas, additional, Spigelman, Allan D, additional, Azzabi, Ashraf, additional, Helfand, Brian T, additional, Halliday, Dorothy, additional, Buys, Saundra, additional, Ramon y Cajal, Teresa, additional, Donaldson, Alan, additional, Cooney, Kathleen A, additional, Harris, Marion, additional, McGrath, John, additional, Davidson, Rosemarie, additional, Taylor, Amy, additional, Cooke, Peter, additional, Myhill, Kathryn, additional, Hogben, Matthew, additional, Aaronson, Neil K, additional, Ardern-Jones, Audrey, additional, Bangma, Chris H, additional, Castro, Elena, additional, Dearnaley, David, additional, Dias, Alexander, additional, Dudderidge, Tim, additional, Eccles, Diana M, additional, Green, Kate, additional, Eyfjord, Jorunn, additional, Falconer, Alison, additional, Foster, Christopher S, additional, Gronberg, Henrik, additional, Hamdy, Freddie C, additional, Johannsson, Oskar, additional, Khoo, Vincent, additional, Lilja, Hans, additional, Lindeman, Geoffrey J, additional, Lubinski, Jan, additional, Axcrona, Karol, additional, Mikropoulos, Christos, additional, Mitra, Anita V, additional, Moynihan, Clare, additional, Ni Raghallaigh, Holly, additional, Rennert, Gad, additional, Collier, Rebecca, additional, Offman, Judith, additional, Kote-Jarai, Zsofia, additional, Eeles, Rosalind A, additional, Adams, Lisa, additional, Adlard, Julian, additional, Alfonso, Rosa, additional, Ali, Saira, additional, Andrew, Angela, additional, Araújo, Luís, additional, Azam, Nazya, additional, Ball, Darran, additional, Barker, Queenstone, additional, Basevitch, Alon, additional, Benton, Barbara, additional, Berlin, Cheryl, additional, Bermingham, Nicola, additional, Biller, Leah, additional, Bloss, Angela, additional, Bradford, Matilda, additional, Bradshaw, Nicola, additional, Branson, Amy, additional, Brendler, Charles, additional, Brennan, Maria, additional, Bulman, Barbara, additional, Burgess, Lucy, additional, Cahill, Declan, additional, Callard, Alice, additional, Calvo Verges, Nuria, additional, Cardoso, Marta, additional, Carter, Vanda, additional, Catanzaro, Mario, additional, Chamberlain, Anthony, additional, Chapman, Cyril, additional, Chong, Michael, additional, Clark, Caroline, additional, Clowes, Virginia, additional, Cogley, Lyn, additional, Cole, Trevor, additional, Compton, Cecilia, additional, Conner, Tom, additional, Cookson, Sandra, additional, Cornford, Philip, additional, Costello, Philandra, additional, Coulier, Laura, additional, Davies, Michaela, additional, Dechet, Christopher, additional, DeSouza, Bianca, additional, Devlin, Gemma, additional, Douglas, Fiona, additional, Douglas, Emma, additional, Dudakia, Darshna, additional, Duncan, Alexis, additional, Ellery, Natalie, additional, Everest, Sarah, additional, Freemantle, Sue, additional, Frydenberg, Mark, additional, Fuller, Debbie, additional, Gabriel, Camila, additional, Gale, Madeline, additional, Garcia, Lynda, additional, Gay, Simona, additional, Genova, Elena, additional, George, Angela, additional, Georgiou, Demetra, additional, Gisbert, Alexandra, additional, Gleeson, Margaret, additional, Glover, Wayne, additional, Gnanapragasam, Vincent, additional, Goff, Sally, additional, Goldgar, David, additional, Gonçalves, Nuno, additional, Goodman, Selina, additional, Gorrie, Jennifer, additional, Gott, Hannah, additional, Grant, Anna, additional, Gray, Catherine, additional, Griffiths, Julie, additional, Gupwell, Karin, additional, Gurasashvili, Jana, additional, Hanslien, Eldbjørg, additional, Haraldsdottir, Sigurdis, additional, Hart, Rachel, additional, Hartigan, Catherine, additional, Hawkes, Lara, additional, Heaton, Tricia, additional, Henderson, Alex, additional, Henrique, Rui, additional, Hilario, Kathrine, additional, Hill, Kathryn, additional, Hulick, Peter, additional, Hunt, Clare, additional, Hutchings, Melanie, additional, Ibitoye, Rita, additional, Inglehearn, Thomas, additional, Ireland, Joanna, additional, Islam, Farah, additional, Ismail, Siti, additional, Jacobs, Chris, additional, James, Denzil, additional, Jenkins, Sharon, additional, Jobson, Irene, additional, Johnstone, Anne, additional, Jones, Oliver, additional, Josefsberg Ben-Yehoshua, Sagi, additional, Kaemba, Beckie, additional, Kaul, Karen, additional, Kemp, Zoe, additional, Kinsella, Netty, additional, Klehm, Margaret, additional, Kockelbergh, Roger, additional, Kohut, Kelly, additional, Kosicka-Slawinska, Monika, additional, Kulkarni, Anjana, additional, Kumar, Pardeep, additional, Lam, Jimmy, additional, LeButt, Mandy, additional, Leibovici, Dan, additional, Lim, Ramona, additional, Limb, Lauren, additional, Lomas, Claire, additional, Longmuir, Mark, additional, López, Consol, additional, Magnani, Tiziana, additional, Maia, Sofia, additional, Maiden, Jessica, additional, Male, Alison, additional, Manalo, Merrie, additional, Martin, Phoebe, additional, McBride, Donna, additional, McGuire, Michael, additional, McMahon, Romayne, additional, McNally, Claire, additional, McVeigh, Terri, additional, Melzer, Ehud, additional, Mencias, Mark, additional, Mercer, Catherine, additional, Mitchell, Gillian, additional, Mora, Josefina, additional, Morton, Catherine, additional, Moss, Cathryn, additional, Murphy, Morgan, additional, Murphy, Declan, additional, Mzazi, Shumi, additional, Nadolski, Maria, additional, Newlin, Anna, additional, Nogueira, Pedro, additional, O'Keefe, Rachael, additional, O'Toole, Karen, additional, O'Connell, Shona, additional, Ogden, Chris, additional, Okoth, Linda, additional, Oliveira, Jorge, additional, Paez, Edgar, additional, Palou, Joan, additional, Park, Linda, additional, Patel, Nafisa, additional, Paulo Souto, João, additional, Pearce, Allison, additional, Peixoto, Ana, additional, Perez, Kimberley, additional, Petelin, Lara, additional, Pichert, Gabriella, additional, Poile, Charlotte, additional, Potter, Alison, additional, Preitner, Nadia, additional, Purnell, Helen, additional, Quinn, Ellen, additional, Radice, Paolo, additional, Rankin, Brigette, additional, Rees, Katie, additional, Renton, Caroline, additional, Richardson, Kate, additional, Risby, Peter, additional, Rogers, Jason, additional, Ruderman, Maggie, additional, Ruiz, April, additional, Sajoo, Anaar, additional, Salvatore, Natale, additional, Sands, Victoria, additional, Sanguedolce, Francesco, additional, Sattar, Ayisha, additional, Saunders, Kathryn, additional, Schofield, Lyn, additional, Scott, Rodney, additional, Searle, Anne, additional, Sehra, Ravinder, additional, Selkirk, Christina, additional, Shackleton, Kylie, additional, Shanley, Sue, additional, Shaw, Adam, additional, Shevrin, Daniel, additional, Shipman, Hannah, additional, Sidat, Zahirah, additional, Siguake, Kas, additional, Simon, Kate, additional, Smyth, Courtney, additional, Snadden, Lesley, additional, Solanky, Nita, additional, Solomons, Joyce, additional, Sorrentino, Margherita, additional, Stayner, Barbara, additional, Stephenson, Robert, additional, Stoffel, Elena, additional, Thomas, Maggie, additional, Thompson, Alan, additional, Tidey, Lizzie, additional, Tischkowitz, Marc, additional, Torokwa, Audrey, additional, Townshend, Sharron, additional, Treherne, Katy, additional, Tricker, Karen, additional, Trinh, Quoc-Dien, additional, Tripathi, Vishakha, additional, Turnbull, Clare, additional, Valdagni, Riccardo, additional, Van As, Nicholas, additional, Venne, Vickie, additional, Verdon, Lizzie, additional, Vitellaro, Marco, additional, Vogel, Kristen, additional, Walker, Lisa, additional, Watford, Amy, additional, Watt, Cathy, additional, Weintroub, Ilana, additional, Weiss, Shelly, additional, Weissman, Scott, additional, Weston, Michelle, additional, Wiggins, Jennifer, additional, Wise, Gillian, additional, Woodhouse, Christopher, additional, Yesildag, Pembe, additional, Youngs, Alice, additional, Yurgelun, Matthew, additional, and Zollo, Fabiana, additional

Published
2021
Full Text
View/download PDF

13. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen A., Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S.., Paul, James, and Universitat Autònoma de Barcelona

Subjects
Male, Time Factors, Organoplatinum Compounds, Leucovorin, Peripheral Nervous System Diseases, Adenocarcinoma, Middle Aged, Disease-Free Survival, Oxaliplatin, Survival Rate, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Chemotherapy, Humans, Female, Fluorouracil, Colorectal Neoplasms, Capecitabine, Aged, Neoplasm Staging
Abstract

6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1-78·2) for the 3 month group and 77·1% (75·6-78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909-1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.

Published
2021

14. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT) : initial results from an international prospective study

Author

Bancroft, Elizabeth K, Page, Elizabeth C, Brook, Mark N, Thomas, Sarah, Taylor, Natalie, Pope, Jennifer, McHugh, Jana, Jones, Ann-Britt, Karlsson, Questa, Merson, Susan, Ong, Kai Ren, Hoffman, Jonathan, Huber, Camilla, Maehle, Lovise, Grindedal, Eli Marie, Stormorken, Astrid, Evans, D Gareth, Rothwell, Jeanette, Lalloo, Fiona, Brady, Angela F, Bartlett, Marion, Snape, Katie, Hanson, Helen, James, Paul, McKinley, Joanne, Mascarenhas, Lyon, Syngal, Sapna, Ukaegbu, Chinedu, Side, Lucy, Thomas, Tessy, Barwell, Julian, Teixeira, Manuel R, Izatt, Louise, Suri, Mohnish, Macrae, Finlay A, Poplawski, Nicola, Chen-Shtoyerman, Rakefet, Ahmed, Munaza, Musgrave, Hannah, Nicolai, Nicola, Greenhalgh, Lynn, Brewer, Carole, Pachter, Nicholas, Spigelman, Allan D, Azzabi, Ashraf, Helfand, Brian T, Halliday, Dorothy, Buys, Saundra, Ramon y Cajal, Teresa, Donaldson, Alan, Cooney, Kathleen A, Harris, Marion, McGrath, John, Davidson, Rosemarie, Taylor, Amy, Cooke, Peter, Myhill, Kathryn, Hogben, Matthew, Aaronson, Neil K, Ardern-Jones, Audrey, Bangma, Chris H, Castro, Elena, Dearnaley, David, Dias, Alexander, Dudderidge, Tim, Eccles, Diana M, Green, Kate, Eyfjord, Jorunn, Falconer, Alison, Foster, Christopher S, Gronberg, Henrik, Hamdy, Freddie C, Johannsson, Oskar, Khoo, Vincent, Lilja, Hans, Lindeman, Geoffrey J, Lubinski, Jan, Axcrona, Karol, Mikropoulos, Christos, Mitra, Anita V, Moynihan, Clare, Ni Raghallaigh, Holly, Rennert, Gad, Collier, Rebecca, Offman, Judith, Kote-Jarai, Zsofia, Eeles, Rosalind A, Universitat Autònoma de Barcelona, Bancroft, Elizabeth K, Page, Elizabeth C, Brook, Mark N, Thomas, Sarah, Taylor, Natalie, Pope, Jennifer, McHugh, Jana, Jones, Ann-Britt, Karlsson, Questa, Merson, Susan, Ong, Kai Ren, Hoffman, Jonathan, Huber, Camilla, Maehle, Lovise, Grindedal, Eli Marie, Stormorken, Astrid, Evans, D Gareth, Rothwell, Jeanette, Lalloo, Fiona, Brady, Angela F, Bartlett, Marion, Snape, Katie, Hanson, Helen, James, Paul, McKinley, Joanne, Mascarenhas, Lyon, Syngal, Sapna, Ukaegbu, Chinedu, Side, Lucy, Thomas, Tessy, Barwell, Julian, Teixeira, Manuel R, Izatt, Louise, Suri, Mohnish, Macrae, Finlay A, Poplawski, Nicola, Chen-Shtoyerman, Rakefet, Ahmed, Munaza, Musgrave, Hannah, Nicolai, Nicola, Greenhalgh, Lynn, Brewer, Carole, Pachter, Nicholas, Spigelman, Allan D, Azzabi, Ashraf, Helfand, Brian T, Halliday, Dorothy, Buys, Saundra, Ramon y Cajal, Teresa, Donaldson, Alan, Cooney, Kathleen A, Harris, Marion, McGrath, John, Davidson, Rosemarie, Taylor, Amy, Cooke, Peter, Myhill, Kathryn, Hogben, Matthew, Aaronson, Neil K, Ardern-Jones, Audrey, Bangma, Chris H, Castro, Elena, Dearnaley, David, Dias, Alexander, Dudderidge, Tim, Eccles, Diana M, Green, Kate, Eyfjord, Jorunn, Falconer, Alison, Foster, Christopher S, Gronberg, Henrik, Hamdy, Freddie C, Johannsson, Oskar, Khoo, Vincent, Lilja, Hans, Lindeman, Geoffrey J, Lubinski, Jan, Axcrona, Karol, Mikropoulos, Christos, Mitra, Anita V, Moynihan, Clare, Ni Raghallaigh, Holly, Rennert, Gad, Collier, Rebecca, Offman, Judith, Kote-Jarai, Zsofia, Eeles, Rosalind A, and Universitat Autònoma de Barcelona

Abstract

Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered wi

Published
2021

15. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT):initial results from an international prospective study

Author

Bancroft, Elizabeth K., Page, Elizabeth C., Brook, Mark N., Thomas, Sarah, Taylor, Natalie, Pope, Jennifer, McHugh, Jana, Jones, Ann Britt, Karlsson, Questa, Merson, Susan, Ong, Kai Ren, Hoffman, Jonathan, Huber, Camilla, Maehle, Lovise, Grindedal, Eli Marie, Stormorken, Astrid, Evans, D. Gareth, Rothwell, Jeanette, Lalloo, Fiona, Brady, Angela F., Bartlett, Marion, Snape, Katie, Hanson, Helen, James, Paul, McKinley, Joanne, Mascarenhas, Lyon, Syngal, Sapna, Ukaegbu, Chinedu, Side, Lucy, Thomas, Tessy, Barwell, Julian, Teixeira, Manuel R., Izatt, Louise, Suri, Mohnish, Macrae, Finlay A., Poplawski, Nicola, Chen-Shtoyerman, Rakefet, Ahmed, Munaza, Musgrave, Hannah, Nicolai, Nicola, Greenhalgh, Lynn, Brewer, Carole, Pachter, Nicholas, Spigelman, Allan D., Azzabi, Ashraf, Helfand, Brian T., Halliday, Dorothy, Buys, Saundra, Ramon Y Cajal, Teresa, Bangma, Chris H., Kote-Jarai, Zsofia, Eeles, Rosalind A., Bancroft, Elizabeth K., Page, Elizabeth C., Brook, Mark N., Thomas, Sarah, Taylor, Natalie, Pope, Jennifer, McHugh, Jana, Jones, Ann Britt, Karlsson, Questa, Merson, Susan, Ong, Kai Ren, Hoffman, Jonathan, Huber, Camilla, Maehle, Lovise, Grindedal, Eli Marie, Stormorken, Astrid, Evans, D. Gareth, Rothwell, Jeanette, Lalloo, Fiona, Brady, Angela F., Bartlett, Marion, Snape, Katie, Hanson, Helen, James, Paul, McKinley, Joanne, Mascarenhas, Lyon, Syngal, Sapna, Ukaegbu, Chinedu, Side, Lucy, Thomas, Tessy, Barwell, Julian, Teixeira, Manuel R., Izatt, Louise, Suri, Mohnish, Macrae, Finlay A., Poplawski, Nicola, Chen-Shtoyerman, Rakefet, Ahmed, Munaza, Musgrave, Hannah, Nicolai, Nicola, Greenhalgh, Lynn, Brewer, Carole, Pachter, Nicholas, Spigelman, Allan D., Azzabi, Ashraf, Helfand, Brian T., Halliday, Dorothy, Buys, Saundra, Ramon Y Cajal, Teresa, Bangma, Chris H., Kote-Jarai, Zsofia, and Eeles, Rosalind A.

Abstract

BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHODS: The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. Thi

Published
2021

17. CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.

Author

Staehler, Michael D., primary, Hamberg, Paul, additional, Bigot, Pierre, additional, Suárez, Cristina, additional, Barthelemy, Philippe, additional, Eymard, Jean-Christophe, additional, Laramas, Mathieu, additional, Taguieva Pioger, Naila, additional, Gross-Goupil, Marine, additional, Rink, Michael, additional, Masini, Cristina, additional, De Vivo, Rocco, additional, Gajate, Pablo, additional, Azzabi, Ashraf, additional, and Procopio, Giuseppe, additional

Published
2020
Full Text
View/download PDF

18. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Author

Iveson, Timothy, primary, Boyd, Kathleen A, additional, Kerr, Rachel S, additional, Robles-Zurita, Jose, additional, Saunders, Mark P, additional, Briggs, Andrew H, additional, Cassidy, Jim, additional, Hollander, Niels Henrik, additional, Tabernero, Josep, additional, Haydon, Andrew, additional, Glimelius, Bengt, additional, Harkin, Andrea, additional, Allan, Karen, additional, McQueen, John, additional, Pearson, Sarah, additional, Waterston, Ashita, additional, Medley, Louise, additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Dhadda, Amandeep S, additional, Harrison, Mark, additional, Falk, Stephen, additional, Raouf, Sherif, additional, Rees, Charlotte, additional, Olesen, Rene K, additional, Propper, David, additional, Bridgewater, John, additional, Azzabi, Ashraf, additional, Farrugia, David, additional, Webb, Andrew, additional, Cunningham, David, additional, Hickish, Tamas, additional, Weaver, Andrew, additional, Gollins, Simon, additional, Wasan, Harpreet, additional, and Paul, James, additional

Published
2019
Full Text
View/download PDF

19. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Author

Page, Elizabeth C., primary, Bancroft, Elizabeth K., additional, Brook, Mark N., additional, Assel, Melissa, additional, Hassan Al Battat, Mona, additional, Thomas, Sarah, additional, Taylor, Natalie, additional, Chamberlain, Anthony, additional, Pope, Jennifer, additional, Raghallaigh, Holly Ni, additional, Evans, D. Gareth, additional, Rothwell, Jeanette, additional, Maehle, Lovise, additional, Grindedal, Eli Marie, additional, James, Paul, additional, Mascarenhas, Lyon, additional, McKinley, Joanne, additional, Side, Lucy, additional, Thomas, Tessy, additional, van Asperen, Christi, additional, Vasen, Hans, additional, Kiemeney, Lambertus A., additional, Ringelberg, Janneke, additional, Jensen, Thomas Dyrsø, additional, Osther, Palle J.S., additional, Helfand, Brian T., additional, Genova, Elena, additional, Oldenburg, Rogier A., additional, Cybulski, Cezary, additional, Wokolorczyk, Dominika, additional, Ong, Kai-Ren, additional, Huber, Camilla, additional, Lam, Jimmy, additional, Taylor, Louise, additional, Salinas, Monica, additional, Feliubadaló, Lidia, additional, Oosterwijk, Jan C., additional, van Zelst-Stams, Wendy, additional, Cook, Jackie, additional, Rosario, Derek J., additional, Domchek, Susan, additional, Powers, Jacquelyn, additional, Buys, Saundra, additional, O'Toole, Karen, additional, Ausems, Margreet G.E.M., additional, Schmutzler, Rita K., additional, Rhiem, Kerstin, additional, Izatt, Louise, additional, Tripathi, Vishakha, additional, Teixeira, Manuel R., additional, Cardoso, Marta, additional, Foulkes, William D., additional, Aprikian, Armen, additional, van Randeraad, Heleen, additional, Davidson, Rosemarie, additional, Longmuir, Mark, additional, Ruijs, Mariëlle W.G., additional, Helderman van den Enden, Apollonia T.J.M., additional, Adank, Muriel, additional, Williams, Rachel, additional, Andrews, Lesley, additional, Murphy, Declan G., additional, Halliday, Dorothy, additional, Walker, Lisa, additional, Liljegren, Annelie, additional, Carlsson, Stefan, additional, Azzabi, Ashraf, additional, Jobson, Irene, additional, Morton, Catherine, additional, Shackleton, Kylie, additional, Snape, Katie, additional, Hanson, Helen, additional, Harris, Marion, additional, Tischkowitz, Marc, additional, Taylor, Amy, additional, Kirk, Judy, additional, Susman, Rachel, additional, Chen-Shtoyerman, Rakefet, additional, Spigelman, Allan, additional, Pachter, Nicholas, additional, Ahmed, Munaza, additional, Ramon y Cajal, Teresa, additional, Zgajnar, Janez, additional, Brewer, Carole, additional, Gadea, Neus, additional, Brady, Angela F., additional, van Os, Theo, additional, Gallagher, David, additional, Johannsson, Oskar, additional, Donaldson, Alan, additional, Barwell, Julian, additional, Nicolai, Nicola, additional, Friedman, Eitan, additional, Obeid, Elias, additional, Greenhalgh, Lynn, additional, Murthy, Vedang, additional, Copakova, Lucia, additional, Saya, Sibel, additional, McGrath, John, additional, Cooke, Peter, additional, Rønlund, Karina, additional, Richardson, Kate, additional, Henderson, Alex, additional, Teo, Soo H., additional, Arun, Banu, additional, Kast, Karin, additional, Dias, Alexander, additional, Aaronson, Neil K., additional, Ardern-Jones, Audrey, additional, Bangma, Chris H., additional, Castro, Elena, additional, Dearnaley, David, additional, Eccles, Diana M., additional, Tricker, Karen, additional, Eyfjord, Jorunn, additional, Falconer, Alison, additional, Foster, Christopher, additional, Gronberg, Henrik, additional, Hamdy, Freddie C., additional, Stefansdottir, Vigdis, additional, Khoo, Vincent, additional, Lindeman, Geoffrey J., additional, Lubinski, Jan, additional, Axcrona, Karol, additional, Mikropoulos, Christos, additional, Mitra, Anita, additional, Moynihan, Clare, additional, Rennert, Gadi, additional, Suri, Mohnish, additional, Wilson, Penny, additional, Dudderidge, Tim, additional, Offman, Judith, additional, Kote-Jarai, Zsofia, additional, Vickers, Andrew, additional, Lilja, Hans, additional, and Eeles, Rosalind A., additional

Published
2019
Full Text
View/download PDF

20. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengy, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., and Paul, James

Subjects
Male, Cancer och onkologi, Time Factors, Organoplatinum Compounds, Leucovorin, Peripheral Nervous System Diseases, Adenocarcinoma, Middle Aged, Disease-Free Survival, Oxaliplatin, Survival Rate, Chemotherapy, Adjuvant, Cancer and Oncology, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Fluorouracil, Colorectal Neoplasms, Capecitabine, Aged, Neoplasm Staging
Abstract

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1–78·2) for the 3 month group and 77·1% (75·6–78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909–1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). Interpretation: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Funding: Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.

Published
2019

21. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Author

Page, Elizabeth C., Bancroft, Elizabeth K., Brook, Mark N., Assel, Melissa, Al Battat, Mona Hassan, Thomas, Sarah, Taylor, Natalie, Chamberlain, Anthony, Pope, Jennifer, Ni Raghallaigh, Holly, Evans, D. Gareth, Rothwell, Jeanette, Maehle, Lovise, Grindedal, Eli Marie, James, Paul, Mascarenhas, Lyon, McKinley, Joanne, Side, Lucy, Thomas, Tessy, van Asperen, Christi, Vasen, Hans, Kiemeney, Lambertus A., Ringelberg, Janneke, Jensen, Thomas Dyrso, Osther, Palle J. S., Helfand, Brian T., Genova, Elena, Oldenburg, Rogier A., Cybulski, Cezary, Wokolorczyk, Dominika, Ong, Kai-Ren, Huber, Camilla, Lam, Jimmy, Taylor, Louise, Salinas, Monica, Feliubadalo, Lidia, Oosterwijk, Jan C., van Zelst-Stams, Wendy, Cook, Jackie, Rosario, Derek J., Domchek, Susan, Powers, Jacquelyn, Buys, Saundra, O'Toole, Karen, Ausems, Margreet G. E. M., Schmutzler, Rita K., Rhiem, Kerstin, Izatt, Louise, Tripathi, Vishakha, Teixeira, Manuel R., Cardoso, Marta, Foulkes, William D., Aprikian, Armen, van Randeraad, Heleen, Davidson, Rosemarie, Longmuir, Mark, Ruijs, Marielle W. G., Helderman van den Enden, Apollonia T. J. M., Adank, Muriel, Williams, Rachel, Andrews, Lesley, Murphy, Declan G., Halliday, Dorothy, Walker, Lisa, Liljegren, Annelie, Carlsson, Stefan, Azzabi, Ashraf, Jobson, Irene, Morton, Catherine, Shackleton, Kylie, Snape, Katie, Hanson, Helen, Harris, Marion, Tischkowitz, Marc, Taylor, Amy, Kirk, Judy, Susman, Rachel, Chen-Shtoyerman, Rakefet, Spigelman, Allan, Pachter, Nicholas, Ahmed, Munaza, Ramon y Cajal, Teresa, Zgajnar, Janez, Brewer, Carole, Gadea, Neus, Brady, Angela F., van Os, Theo, Gallagher, David, Johannsson, Oskar, Donaldson, Alan, Barwell, Julian, Nicolai, Nicola, Friedman, Eitan, Obeid, Elias, Greenhalgh, Lynn, Murthy, Vedang, Copakova, Lucia, Saya, Sibel, McGrath, John, Cooke, Peter, Ronlund, Karina, Richardson, Kate, Henderson, Alex, Teo, Soo H., Arun, Banu, Kast, Karin, Dias, Alexander, Aaronson, Neil K., Ardern-Jones, Audrey, Bangma, Chris H., Castro, Elena, Dearnaley, David, Eccles, Diana M., Tricker, Karen, Eyfjord, Jorunn, Falconer, Alison, Foster, Christopher, Gronberg, Henrik, Hamdy, Freddie C., Stefansdottir, Vigdis, Khoo, Vincent, Lindeman, Geoffrey J., Lubinski, Jan, Axcrona, Karol, Mikropoulos, Christos, Mitra, Anita, Moynihan, Clare, Rennert, Gadi, Suri, Mohnish, Wilson, Penny, Dudderidge, Tim, Offman, Judith, Kote-Jarai, Zsofia, Vickers, Andrew, Lilja, Hans, Eeles, Rosalind A., Page, Elizabeth C., Bancroft, Elizabeth K., Brook, Mark N., Assel, Melissa, Al Battat, Mona Hassan, Thomas, Sarah, Taylor, Natalie, Chamberlain, Anthony, Pope, Jennifer, Ni Raghallaigh, Holly, Evans, D. Gareth, Rothwell, Jeanette, Maehle, Lovise, Grindedal, Eli Marie, James, Paul, Mascarenhas, Lyon, McKinley, Joanne, Side, Lucy, Thomas, Tessy, van Asperen, Christi, Vasen, Hans, Kiemeney, Lambertus A., Ringelberg, Janneke, Jensen, Thomas Dyrso, Osther, Palle J. S., Helfand, Brian T., Genova, Elena, Oldenburg, Rogier A., Cybulski, Cezary, Wokolorczyk, Dominika, Ong, Kai-Ren, Huber, Camilla, Lam, Jimmy, Taylor, Louise, Salinas, Monica, Feliubadalo, Lidia, Oosterwijk, Jan C., van Zelst-Stams, Wendy, Cook, Jackie, Rosario, Derek J., Domchek, Susan, Powers, Jacquelyn, Buys, Saundra, O'Toole, Karen, Ausems, Margreet G. E. M., Schmutzler, Rita K., Rhiem, Kerstin, Izatt, Louise, Tripathi, Vishakha, Teixeira, Manuel R., Cardoso, Marta, Foulkes, William D., Aprikian, Armen, van Randeraad, Heleen, Davidson, Rosemarie, Longmuir, Mark, Ruijs, Marielle W. G., Helderman van den Enden, Apollonia T. J. M., Adank, Muriel, Williams, Rachel, Andrews, Lesley, Murphy, Declan G., Halliday, Dorothy, Walker, Lisa, Liljegren, Annelie, Carlsson, Stefan, Azzabi, Ashraf, Jobson, Irene, Morton, Catherine, Shackleton, Kylie, Snape, Katie, Hanson, Helen, Harris, Marion, Tischkowitz, Marc, Taylor, Amy, Kirk, Judy, Susman, Rachel, Chen-Shtoyerman, Rakefet, Spigelman, Allan, Pachter, Nicholas, Ahmed, Munaza, Ramon y Cajal, Teresa, Zgajnar, Janez, Brewer, Carole, Gadea, Neus, Brady, Angela F., van Os, Theo, Gallagher, David, Johannsson, Oskar, Donaldson, Alan, Barwell, Julian, Nicolai, Nicola, Friedman, Eitan, Obeid, Elias, Greenhalgh, Lynn, Murthy, Vedang, Copakova, Lucia, Saya, Sibel, McGrath, John, Cooke, Peter, Ronlund, Karina, Richardson, Kate, Henderson, Alex, Teo, Soo H., Arun, Banu, Kast, Karin, Dias, Alexander, Aaronson, Neil K., Ardern-Jones, Audrey, Bangma, Chris H., Castro, Elena, Dearnaley, David, Eccles, Diana M., Tricker, Karen, Eyfjord, Jorunn, Falconer, Alison, Foster, Christopher, Gronberg, Henrik, Hamdy, Freddie C., Stefansdottir, Vigdis, Khoo, Vincent, Lindeman, Geoffrey J., Lubinski, Jan, Axcrona, Karol, Mikropoulos, Christos, Mitra, Anita, Moynihan, Clare, Rennert, Gadi, Suri, Mohnish, Wilson, Penny, Dudderidge, Tim, Offman, Judith, Kote-Jarai, Zsofia, Vickers, Andrew, Lilja, Hans, and Eeles, Rosalind A.

Abstract

Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/ 2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA> 3.0 ng/ml, men were offered prostate biopsy. Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p= 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biop

Published
2019

25. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Henrik Hollander, Niels, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., Paul, James, Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Henrik Hollander, Niels, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., and Paul, James

Abstract

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1: 1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1.13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76.7% (95% CI 75.1-78.

Published
2018
Full Text
View/download PDF

26. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Author

Iveson, Timothy J, primary, Kerr, Rachel S, additional, Saunders, Mark P, additional, Cassidy, Jim, additional, Hollander, Niels Henrik, additional, Tabernero, Josep, additional, Haydon, Andrew, additional, Glimelius, Bengt, additional, Harkin, Andrea, additional, Allan, Karen, additional, McQueen, John, additional, Scudder, Claire, additional, Boyd, Kathleen Anne, additional, Briggs, Andrew, additional, Waterston, Ashita, additional, Medley, Louise, additional, Wilson, Charles, additional, Ellis, Richard, additional, Essapen, Sharadah, additional, Dhadda, Amandeep S, additional, Harrison, Mark, additional, Falk, Stephen, additional, Raouf, Sherif, additional, Rees, Charlotte, additional, Olesen, Rene K, additional, Propper, David, additional, Bridgewater, John, additional, Azzabi, Ashraf, additional, Farrugia, David, additional, Webb, Andrew, additional, Cunningham, David, additional, Hickish, Tamas, additional, Weaver, Andrew, additional, Gollins, Simon, additional, Wasan, Harpreet S, additional, and Paul, James, additional

Published
2018
Full Text
View/download PDF

28. Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study.

Author

Pearson, Rachel Anne, primary, Thelwall, Pete E, additional, Snell, Jim, additional, McKenna, Jill, additional, Pieniazek, Piotr, additional, Fitzgerald, Emily Louise, additional, Heer, Rakesh, additional, McMenemin, Rhona Margaret, additional, Pedley, Ian D., additional, Azzabi, Ashraf S., additional, Newell, Herbie, additional, Maxwell, Ross J., additional, Plummer, Elizabeth R., additional, and Frew, John A., additional

Published
2016
Full Text
View/download PDF

29. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer

Author

Rajan, Prabhakar, primary, Frew, John A., additional, Wilson, James M., additional, Azzabi, Ashraf S.T., additional, McMenemin, Rhona M., additional, Stockley, Jacqueline, additional, Soomro, Naeem A., additional, Durkan, Garrett, additional, Pedley, Ian D., additional, and Leung, Hing Y., additional

Published
2015
Full Text
View/download PDF

30. Stage I testicular tumor: How frequently to scan?

Author

Ramamurthy, Sindhu, primary, Mahtab, Najibah, additional, Showler, Helen, additional, Frew, John A., additional, Pedley, Ian D., additional, Azzabi, Ashraf, additional, Brown, Jolene, additional, and McMenemin, Rhona Margaret, additional

Published
2014
Full Text
View/download PDF

32. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.

Author

Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S, Eeles RA, and Aaronson NK

Subjects
Humans, Male, Middle Aged, Aged, Quality of Life, Genes, BRCA1, Surveys and Questionnaires, Genes, BRCA2, Heterozygote, Anxiety etiology, Longitudinal Studies, Prostatic Neoplasms psychology, Prostatic Neoplasms genetics, Prostatic Neoplasms diagnosis, Genetic Predisposition to Disease psychology, Early Detection of Cancer psychology
Abstract

Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2)., Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge., Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time., Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups., (© 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results